Becton Dickinson's most recent trend suggests a bullish bias. One trading opportunity on Becton Dickinson is a Bull Put Spread using a strike $125.00 short put and a strike $115.00 long put offers a potential 11.11% return on risk over the next 19 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $125.00 by expiration. The full premium credit of $1.00 would be kept by the premium seller. The risk of $9.00 would be incurred if the stock dropped below the $115.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Becton Dickinson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Becton Dickinson is bullish.
The RSI indicator is at 58.71 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Becton Dickinson
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates?
Fri, 31 Oct 2014 19:53:52 GMT
Unexpected Obamacare boost
Mon, 27 Oct 2014 18:41:00 GMT
Becton, Dickinson Acquires GenCell Biosystems in Ireland
Tue, 14 Oct 2014 16:10:08 GMT
BD Acquires GenCell Biosystems
Mon, 13 Oct 2014 12:00:00 GMT
PR Newswire – FRANKLIN LAKES, N.J., Oct. 13, 2014 /PRNewswire/ — BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications. “We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD. “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”
Sat, 11 Oct 2014 06:48:00 GMT
Also on Market Tamer…
Follow Us on Facebook